Transform Your Pharmacy’s Growth Potential with ACHC and Monarch Specialty Group. Click Here to learn more




We support a broad collection of relevant news information for clients, as well as organizations evaluating our services.
Get market insights and strategies on orphan drugs and specialty drug pipeline, drug pricing, mergers and acquisitions, and up-to-date payor strategies relating to oncology, infectious disease (Hepatitis-C and HIV), multiple sclerosis, IVIG, and biosimilars, among others:

Plegridy Pushes MS Therapy Options Into Double Digits (with Chart: 20 mg/mL Generic Copaxone and 40 mg/mL Branded Copaxone Management)

… prior authorization or step therapy,” says Stephen Cichy, founder and managing director of Monarch Specialty Group, LLC. “Like … he adds. Also on the rise are costs for the MS drugs. Cichy tells SPN that pricing for these therapies “has easily risen by 50% … September 2014, Specialty Pharmacy News


MS Space Experienced Massive Price Inflation

… in which this trend has been evident, according to Stephen Cichy, founder and managing director for Monarch Specialty Group, LLC during a … was nothing particularly alarming,” said Cichy. During that time period, when there were “no other changes and no … was approved in August 2010, were shared. According to Cichy, “the average cost per claim for Copaxone for March 2012 was $4,088.07, …